Cited by 600Cystic Fibrosis Research AdvancesChronic Obstructive Pulmonary Disease (COPD) ResearchMycobacterium research and diagnosis

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial

Wong, Conroy, Jayaram, Lata, Karalus, Noel, Eaton, Tam, Tong, Cecilia, Hockey, Hans, Milne, David, Fergusson, Wendy, Tuffery, Christine, Sexton, Paul, Storey, Louanne, Ashton, Toni·2012·The Lancet

DOI 10.1016/s0140-6736(12)60953-2

Open this paper in CoChat — free account

Abstract

Background Azithromycin is a macrolide antibiotic with anti-inflammatory and immunomodulatory properties. We tested the hypothesis that azithromycin would decrease the frequency of exacerbations, increase lung function, and improve health-related quality of life in patients with non-cystic fibrosis bronchiectasis.Methods We undertook a randomised, double-blind, placebo-controlled trial at three centres in New Zealand. Between Feb 12, 2008, and Oct 15, 2009, we enrolled patients who were 18 years or older, had had at least one pulmonary exacerbation requiring antibiotic treatment in the past year, and had a diagnosis of bronchiectasis defined by high-resolution CT scan. We randomly assigned patients to receive 500 mg azithromycin or placebo three times a week for 6 months in a 1:1 ratio, with a permuted block size of six and sequential assignment stratified by centre. Participants, research assistants, and investigators were masked to treatment allocation. The coprimary endpoints were rate of event-based exacerbations in the 6-month treatment period, change in forced expiratory volume in 1 s (FEV(1)) before bronchodilation, and change in total score on St George's respiratory questionnaire (SGRQ). Analyses were by intention to treat. This study is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12607000641493.Findings 71 patients were in the azithromycin group and 70 in the placebo group. The rate of event-based exacerbations was 0·59 per patient in the azithromycin group and 1·57 per patient in the placebo group in the 6-month treatment period (rate ratio 0·38, 95% CI 0·26-0·54; p<0·0001). Prebronchodilator FEV(1) did not change from baseline in the azithromycin group and decreased by 0·04 L in the placebo group, but the difference was not significant (0·04 L, 95% CI -0·03 to 0·12; p=0·251). Additionally, change in SGRQ total score did not differ between the azithromycin (-5·17 units) and placebo groups (-1·92 units; difference -3·25, 95% CI -7·21 to 0·72; p=0·108).Interpretation Azithromycin is a new option for prevention of exacerbations in patients with non-cystic fibrosis bronchiectasis with a history of at least one exacerbation in the past year.Funding Health Research Council of New Zealand and Auckland District Health Board Charitable Trust.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(12)60953-2

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

ATS Statement: Guidelines for the Six-Minute Walk Test
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.166.1.at1102 · Cited by 11,195
Azithromycin for prevention of exacerbations of COPD
Albert, R. K., Connett, J., Bailey, W. C., Casaburi, R., Cooper, J. A. D., Criner, G. J., Curtis, J. L., Dransfield, M. T., Han, M. K., Lazarus, S. C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104623 · Cited by 1,226
British Thoracic Society guideline for non-CFbronchiectasis
Pasteur, M. C., Bilton, D., Hill, A. T., & on behalf of the British Thoracic Society Bronchiectasis (non-CF) Guideline Group (2010) · Thorax · doi:10.1136/thx.2010.136119 · Cited by 1,043
Azithromycin in Patients With Cystic Fibrosis Chronically Infected With Pseudomonas aeruginosa: A Randomized Controlled Trial
Saiman, L., Marshall, B. C., Mayer-Hamblett, N., Burns, J. L., Quittner, A. L., Cibene, D. A., Coquillette, S., Fieberg, A. Y., Accurso, F. J., Campbell III, P. W., et al. (2003) · JAMA · doi:10.1001/jama.290.13.1749 · Cited by 958
Azithromycin and the Risk of Cardiovascular Death
Ray, W. A., Murray, K. T., Hall, K., Arbogast, P. G., & Stein, C. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1003833 · Cited by 958
Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory Medications
Kanoh, S., & Rubin, B. K. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00078-09 · Cited by 722
COPD exacerbations: definitions and classifications
Burge, S., & Wedzicha, J. A. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00078002 · Cited by 662
Bronchiectasis
Barker, A. F. (2002) · New England Journal of Medicine · doi:10.1056/nejmra012519 · Cited by 556
Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial
Equi, A., Balfour-Lynn, I. M., Bush, A., & Rosenthal, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11081-6 · Cited by 542
Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study
Malhotra‐Kumar, S., Lammens, C., Coenen, S., Herck, K. V., & Goossens, H. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60235-9 · Cited by 541

Show all 38 references

Sorted by citations

European Respiratory Society guidelines for the management of adult bronchiectasis
Polverino, E., Goeminne, P., McDonnell, M. J., Aliberti, S., Marshall, S. E., Loebinger, M. R., Murris, M., Cantón, R., Torres, A., Dimakou, K., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00629-2017 · Cited by 1,337
The bronchiectasis severity index. An international derivation and validation study
Chalmers, J. D., Goeminne, P., Aliberti, S., McDonnell, M. J., Lonni, S., Davidson, J., Poppelwell, L., Salih, W., Pesci, A., Dupont, L. J., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201309-1575oc · Cited by 1,093
International Consensus Document (ICON): Common Variable Immunodeficiency Disorders
Bonilla, F. A., Barlan, I. B., Chapel, H. M., Costa‐Carvalho, B. T., Cunningham‐Rundles, C., de la Morena, M. T., Espinosa-Rosales, F. J., Hammarström, L. L. G., Nonoyama, S., Quinti, I., et al. (2015) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2015.07.025 · Cited by 876
Tobacco use in 3 billion individuals from 16 countries: an analysis of nationally representative cross-sectional household surveys
Giovino, G. A., Mirza, S. A., Samet, J. M., Gupta, P. C., Jarvis, M. J., Bhala, N., Peto, R., Zatonski, W., Hsia, J., Morton, J., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61085-x · Cited by 740
Azithromycin: Mechanisms of action and their relevance for clinical applications
Parnham, M. J., Haber, V. E., Giamarellos‐Bourboulis, E. J., Perletti, G., Verleden, G. M., & Vos, R. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.03.003 · Cited by 684
British Thoracic Society Guideline for bronchiectasis in adults
Hill, A. T., Sullivan, A., Chalmers, J. D., Soyza, A. D., Elborn, J. S., Floto, R. A., Grillo, L. J., Gruffydd‐Jones, K., Harvey, A., HAWORTH, C. S., et al. (2018) · Thorax · doi:10.1136/thoraxjnl-2018-212463 · Cited by 638
The role of the microbiome in exacerbations of chronic lung diseases
Dickson, R. P., Martinez, F. J., & Huffnagle, G. B. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61136-3 · Cited by 495
Effect of Azithromycin Maintenance Treatment on Infectious Exacerbations Among Patients With Non–Cystic Fibrosis Bronchiectasis
Altenburg, J., de Graaff, C. S., Stienstra, Y., Sloos, J. H., van Haren, E. H. J., Koppers, R. J. H., van der Werf, T. S., & Boersma, W. G. (2013) · JAMA · doi:10.1001/jama.2013.1937 · Cited by 516
Primary Ciliary Dyskinesia. Recent Advances in Diagnostics, Genetics, and Characterization of Clinical Disease
Knowles, M. R., Daniels, L. A., Davis, S. D., Zariwala, M. A., & Leigh, M. W. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201301-0059ci · Cited by 534
Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial
Brusselle, G., VanderStichele, C., Jordens, P., Deman, R., Slabbynck, H., Ringoet, V., Verleden, G. M., Demedts, I., Verhamme, K. M. C., Delporte, A., et al. (2013) · Thorax · doi:10.1136/thoraxjnl-2012-202698 · Cited by 482
The microbiome and critical illness
Dickson, R. P. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00427-0 · Cited by 460
Lung microbiome: new insights into the pathogenesis of respiratory diseases
Li, R., Li, J., & Zhou, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01722-y · Cited by 483
Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research
Hill, A. T., HAWORTH, C. S., Aliberti, S., BARKER, A. R., Blasi, F., Boersma, W. G., Chalmers, J. D., Soyza, A. D., Dimakou, K., Elborn, J. S., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00051-2017 · Cited by 442
Effect of Long-term, Low-Dose Erythromycin on Pulmonary Exacerbations Among Patients With Non–Cystic Fibrosis Bronchiectasis
Serisier, D. J., Martin, M. L., McGuckin, M. A., Lourie, R., Chen, A. C. –., Brain, B., Biga, S., Schlebusch, S., Dash, P., & Bowler, S. (2013) · JAMA · doi:10.1001/jama.2013.2290 · Cited by 419
Motile ciliopathies
Wallmeier, J., Nielsen, K. G., Kuehni, C. E., Lucas, J. S., Leigh, M. W., Zariwala, M. A., & Omran, H. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0209-6 · Cited by 403
Non–Cystic Fibrosis Bronchiectasis
McShane, P. J., Naureckas, E. T., Tino, G., & Strek, M. E. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201303-0411ci · Cited by 390
Bronchiectasis
Chalmers, J. D., Chang, A. B., Chotirmall, S. H., Dhar, R., & McShane, P. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0042-3 · Cited by 366
Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation
Tunney, M. M., Einarsson, G. G., Wei, L., Drain, M., Klem, E. R., Cardwell, C., Ennis, M., Boucher, R. C., Wolfgang, M. C., & Elborn, J. S. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201210-1937oc · Cited by 316
Gut-Lung Axis: The Microbial Contributions and Clinical Implications
He, Y., Wen, Q., Yao, F., Xu, D., Huang, Y., & Wang, J. (2017) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2016.1176988 · Cited by 301
The Immunomodulatory Effects of Macrolides—A Systematic Review of the Underlying Mechanisms
Zimmermann, P., Ziesenitz, V. C., Curtis, N. C., & Ritz, N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00302 · Cited by 308
Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial
Uzun, S., Djamin, R. S., Kluytmans, J. A. J. W., Mulder, P. G. H., Veer, N. E. V. ‘., Ermens, A. A. M., Pelle, A. J. M., Hoogsteden, H. C., Aerts, J. G. J. V., & van der Eerden, M. M. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70019-0 · Cited by 309
Management of bronchiectasis in adults
Chalmers, J. D., Aliberti, S., & Blasi, F. (2015) · European Respiratory Journal · doi:10.1183/09031936.00119114 · Cited by 297
Primary Ciliary Dyskinesia
Knowles, M. R., Zariwala, M. A., & Leigh, M. W. (2016) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2016.04.008 · Cited by 308
Inhaled Colistin in Patients with Bronchiectasis and Chronic Pseudomonas aeruginosa Infection
HAWORTH, C. S., Foweraker, J. E., Wilkinson, P., Kenyon, R. F., & Bilton, D. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201312-2208oc · Cited by 263
The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis
Araújo, D., Shteinberg, M., Aliberti, S., Goeminne, P., Hill, A. T., Fardon, T. C., Obradović, D., Stone, G. A., Trautmann, M., Davis, A., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.01953-2017 · Cited by 261
Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial
Serisier, D. J., Bilton, D., Soyza, A. D., Thompson, P. J., Kolbe, J., Greville, H. W., Cipolla, D. C., Bruinenberg, P., Gonda, I., & the ORBIT-2 investigators (2013) · Thorax · doi:10.1136/thoraxjnl-2013-203207 · Cited by 249
Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study
Keir, H. R., Shoemark, A., Dicker, A., Perea, L., Pollock, J. S., Giam, Y. H., Suárez-Cuartín, G., Crichton, M. L., Lonergan, M. E., Oriano, M., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30504-x · Cited by 248
Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry
Dhar, R., Singh, S., Talwar, D., Mohan, M., V, Tripathi, S. K., Swarnakar, R., Trivedi, S., Rajagopala, S., D′Souza, G., Padmanabhan, A., et al. (2019) · The Lancet Global Health · doi:10.1016/s2214-109x(19)30327-4 · Cited by 247
Co‐morbidities in severe asthma: Clinical impact and management
Porsbjerg, C., & Menzies‐Gow, A. (2017) · Respirology · doi:10.1111/resp.13026 · Cited by 233
Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials
Barker, A. F., O’Donnell, A. E., Flume, P. A., Thompson, P. J., Ruzi, J. D., de Gracia, J., Boersma, W. G., Soyza, A. D., Shao, L., Zhang, J., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70165-1 · Cited by 220
Mortality in non-cystic fibrosis bronchiectasis: A prospective cohort analysis
Goeminne, P., Nawrot, T. S., Ruttens, D., Seys, S., & Dupont, L. (2014) · Respiratory Medicine · doi:10.1016/j.rmed.2013.12.015 · Cited by 216
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials
HAWORTH, C. S., Bilton, D., Chalmers, J. D., Davis, A., Froehlich, J., Gonda, I., Thompson, B., Wanner, A., & O’Donnell, A. E. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30427-2 · Cited by 215
Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration
Aliberti, S., Masefield, S. C., Polverino, E., Soyza, A. D., Loebinger, M. R., Menéndez, R., Ringshausen, F. C., Vendrell, M., Powell, P., & Chalmers, J. D. (2016) · European Respiratory Journal · doi:10.1183/13993003.01888-2015 · Cited by 211
Bronchiectasis: new therapies and new perspectives
Chalmers, J. D., & Chotirmall, S. H. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30053-5 · Cited by 208
Predicting high risk of exacerbations in bronchiectasis: the E-FACED score
Martínez‐García, M. Á., Athanazio, R. A., Girón, R. M., Máiz‐Carro, L., de la Rosa, D., Olveira, C., de Gracia, J., Vendrell, M., Prados‐Sánchez, C., Gramblicka, G., et al. (2017) · International Journal of COPD · doi:10.2147/copd.s121943 · Cited by 208
Primary Ciliary Dyskinesia: An Update on Clinical Aspects, Genetics, Diagnosis, and Future Treatment Strategies
Mirra, V., Werner, C., & Santamaria, F. (2017) · Frontiers in Pediatrics · doi:10.3389/fped.2017.00135 · Cited by 208
Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis
Chalmers, J. D., & Hill, A. T. (2012) · Molecular Immunology · doi:10.1016/j.molimm.2012.09.011 · Cited by 200
Treatment options in type-2 low asthma
Hinks, T., Levine, S. J., & Brusselle, G. (2020) · European Respiratory Journal · doi:10.1183/13993003.00528-2020 · Cited by 202
Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis
Chalmers, J. D., Boersma, W. G., Lonergan, M. E., Jayaram, L., Crichton, M. L., Karalus, N., Taylor, S., Martin, M. L., Burr, L. D., Wong, C., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30191-2 · Cited by 191
Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial
Valery, P. C., Morris, P. S., Byrnes, C. A., Grimwood, K., Torzillo, P. J., Bauert, P., Masters, I. B., Diaz, A., McCallum, G. B., Mobberley, C., et al. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70185-1 · Cited by 189
The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial
Rogers, G. B., Bruce, K. D., Martin, M. L., Burr, L. D., & Serisier, D. J. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70213-9 · Cited by 217
Developments in the diagnosis and treatment of allergic bronchopulmonary aspergillosis
Agarwal, R., Sehgal, I. S., Dhooria, S., & Aggarwal, A. N. (2016) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2016.1249853 · Cited by 178
Bronchiectasis-Associated Hospitalizations in Germany, 2005–2011: A Population-Based Study of Disease Burden and Trends
Ringshausen, F. C., Roux, A. D., Pletz, M. W., Hämäläinen, N., Welte, T., & Rademacher, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071109 · Cited by 168
Spanish Guidelines on Treatment of Bronchiectasis in Adults
Martínez‐García, M. Á., Máiz, L., Olveira, C., Girón, R. M., de la Rosa, D., Blanco, M., Cantón, R., Vendrell, M., Polverino, E., de Gracia, J., et al. (2017) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2017.07.014 · Cited by 164
Normativa sobre el tratamiento de las bronquiectasias en el adulto
Martínez‐García, M. Á., Máiz, L., Olveira, C., Girón, R. M., de la Rosa, D., Blanco, M., Cantón, R., Vendrell, M., Polverino, E., de Gracia, J., et al. (2017) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2017.07.016 · Cited by 157
Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial
Kobbernagel, H. E., Buchvald, F. F., Haarman, E. G., Casaulta, C., Collins, S. A., Hogg, C. L., Kuehni, C. E., Lucas, J. S., Moser, C. E., Quittner, A. L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30058-8 · Cited by 150
Long-term macrolide treatment for chronic respiratory disease
Spagnolo, P., Fabbri, L. M., & Bush, A. (2012) · European Respiratory Journal · doi:10.1183/09031936.00136712 · Cited by 145
Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases
Serisier, D. J. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70038-9 · Cited by 148
Macrolide antibiotics for bronchiectasis
Kelly, C. A., Chalmers, J. D., Crossingham, I. R., Relph, N., Felix, L. M., Evans, D. J., Milan, S. J., & Spencer, S. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012406.pub2 · Cited by 137
Adverse events in people taking macrolide antibiotics versus placebo for any indication
Hansen, M. P., Scott, A. M., McCullough, A. R., Thorning, S., Aronson, J. K., Beller, E., Glasziou, P., Hoffmann, T., Clark, J. M., & Mar, C. D. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011825.pub2 · Cited by 144
Mucolytics for bronchiectasis
Wilkinson, M., Sugumar, K., Milan, S. J., Hart, A., Crockett, A. J., & Crossingham, I. R. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001289.pub2 · Cited by 131
Clinical Practice Guidelines for Diagnosis and Management of Cough—Chinese Thoracic Society (CTS) Asthma Consortium
Lai, K., Shen, H., Zhou, X., Qiu, Z., Shaoxi, C., Huang, K., Wang, Q., Wang, C., Lin, J., Hao, C., et al. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.09.153 · Cited by 140
The immunomodulatory effects of macrolide antibiotics in respiratory disease
Pollock, J. S., & Chalmers, J. D. (2021) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2021.102095 · Cited by 143
Blood, Tissue, and Intracellular Concentrations of Azithromycin during and after End of Therapy
Matzneller, P., Krasniqi, S., Kinzig, M., Sörgel, F., Hüttner, S., Lackner, E., Müller, M., & Zeitlinger, M. A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02011-12 · Cited by 131
Current and Future Treatments in Primary Ciliary Dyskinesia
Paff, T., Omran, H., Nielsen, K. G., & Haarman, E. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189834 · Cited by 128
COPD-related Bronchiectasis; Independent Impact on Disease Course and Outcomes
Gatheral, T. L., Kumar, N., Sansom, B., Lai, D., Nair, A., Vlahos, I., & Baker, E. H. (2014) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.3109/15412555.2014.922174 · Cited by 125
Bronchiectasis management in adults: state of the art and future directions
Choi, H., McShane, P. J., Aliberti, S., & Chalmers, J. D. (2024) · European Respiratory Journal · doi:10.1183/13993003.00518-2024 · Cited by 125
Nontuberculous mycobacterial (NTM) lung disease: The top ten essentials
Aksamit, T. R., Philley, J. V., & Griffith, D. E. (2013) · Respiratory Medicine · doi:10.1016/j.rmed.2013.09.014 · Cited by 117
Azithromycin suppresses CD4+ T-cell activation by direct modulation of mTOR activity
Ratzinger, F., Haslacher, H., Poeppl, W., Hoermann, G., Kovarik, J. J., Jutz, S., Steinberger, P., Burgmann, H., Pickl, W. F., & Schmetterer, K. G. (2014) · Scientific Reports · doi:10.1038/srep07438 · Cited by 113
Comorbidities in interstitial lung diseases
Margaritopoulos, G. A., Antoniou, K. M., & Wells, A. U. (2017) · European Respiratory Review · doi:10.1183/16000617.0027-2016 · Cited by 115
Bronchiectasis: Current Concepts in Pathogenesis, Immunology, and Microbiology
Boyton, R. J., & Altmann, D. M. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044344 · Cited by 113
The role of macrolides in asthma: current evidence and future directions
Wong, E., Porter, J. D., Edwards, M. R., & Johnston, S. L. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70107-9 · Cited by 111
Nonantibiotic Effects of Fluoroquinolones in Mammalian Cells
Badal, S., Her, Y. F., & Maher, L. J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.671222 · Cited by 109
The biology of pulmonary exacerbations in bronchiectasis
Amati, F., Simonetta, E., Gramegna, A., Tarsia, P., Contarini, M., Blasi, F., & Aliberti, S. (2019) · European Respiratory Review · doi:10.1183/16000617.0055-2019 · Cited by 107
Bronchiectasis in China
Lin, J., Xu, J., & Qu, J. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201511-740ps · Cited by 100
Immunomodulatory indications of azithromycin in respiratory disease: a concise review for the clinician
Cramer‐Bour, C., Patterson, A., Alchakaki, A., & Soubani, A. O. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1285677 · Cited by 99
Prescribing azithromycin
McMullan, B. J., & Mostaghim, M. (2015) · Australian Prescriber · doi:10.18773/austprescr.2015.030 · Cited by 99
Lung disease in primary antibody deficiency
Verma, N., Grimbacher, B., & Hurst, J. R. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00202-7 · Cited by 96
Antibiotic Prophylaxis in Primary Immune Deficiency Disorders
Kuruvilla, M. E., & de la Morena, M. T. (2013) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2013.09.013 · Cited by 96
Meta-Analysis of the Adverse Effects of Long-Term Azithromycin Use in Patients with Chronic Lung Diseases
Li, H., Liu, D., Chen, L., Zhao, Q., Yu, Y., Ding, J., Miao, L., Xiao, Y., Cai, H., Zhang, D., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02067-13 · Cited by 96
Antibody Deficiency Secondary to Chronic Lymphocytic Leukemia: Should Patients be Treated with Prophylactic Replacement Immunoglobulin?
Dhalla, F., Lucas, M., Schuh, A., Bhole, M. V., Jain, R., Patel, S. Y., Misbah, S., & Chapel, H. M. (2014) · Journal of Clinical Immunology · doi:10.1007/s10875-014-9995-5 · Cited by 96
Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study
Chalmers, J. D., McHugh, B. J., Doherty, C. J., Smith, M. P., Govan, J. R. W., Kilpatrick, D. C., & Hill, A. T. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70001-8 · Cited by 94
The Effect of Azithromycin in Adults with Stable Neutrophilic COPD: A Double Blind Randomised, Placebo Controlled Trial
Simpson, J. L., Powell, H. A., Baines, K. J., Milne, D. G., Coxson, H. O., Hansbro, P. M., & Gibson, P. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105609 · Cited by 94
Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial
Mandal, P., Chalmers, J. D., Graham, C., Harley, C., Sidhu, M., Doherty, C. J., Govan, J. R. W., Sethi, T., Davidson, D. J., Rossi, A. G., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70050-5 · Cited by 93
Double-blind, placebo-controlled, randomized trial on low-dose azithromycin prophylaxis in patients with primary antibody deficiencies
Milito, C., Pulvirenti, F., Cinetto, F., Lougaris, V., Soresina, A., Pecoraro, A., Vultaggio, A., Carrabba, M., Lassandro, G., Plebani, A., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.01.051 · Cited by 90
Primary ciliary dyskinesia (PCD): A genetic disorder of motile cilia
Leigh, M. W., Horani, A., Kinghorn, B., O’Connor, M. G., Zariwala, M. A., & Knowles, M. R. (2019) · Translational Science of Rare Diseases · doi:10.3233/trd-190036 · Cited by 99
Nonantimicrobial Actions of Macrolides: Overview and Perspectives for Future Development
Kricker, J. A., Page, C. P., Gardarsson, F. R., Baldursson, Ó., Guðjónsson, Þ., & Parnham, M. J. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000300 · Cited by 103
Antibiotic Management of Lung Infections in Cystic Fibrosis. II. Nontuberculous Mycobacteria, Anaerobic Bacteria, and Fungi
Chmiel, J. F., Aksamit, T. R., Chotirmall, S. H., Dasenbrook, E. C., Elborn, J. S., LiPuma, J. J., Ranganathan, S., Waters, V. J., & Ratjen, F. A. (2014) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201405-203as · Cited by 90
Interventions for bronchiectasis: an overview of Cochrane systematic reviews
Welsh, E. J., Evans, D. J., Fowler, S. J., & Spencer, S. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010337.pub2 · Cited by 88
Lung Disease in Primary Antibody Deficiencies
Schussler, E., Beasley, M. B., & Maglione, P. J. (2016) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2016.08.005 · Cited by 88
Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand
Gillis, D., & Riminton, S. (2011) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2011.tb03789.x · Cited by 89
Treatment of Slowly Growing Mycobacteria
Philley, J. V., & Griffith, D. E. (2014) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2014.10.005 · Cited by 86
Pseudomonas aeruginosa in bronchiectasis: infection, inflammation, and therapies
Vidaillac, C., & Chotirmall, S. H. (2021) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2021.1906225 · Cited by 86
Antibiotics for treatment and prevention of exacerbations of chronic obstructive pulmonary disease
Wilson, R., Sethi, S., Anzueto, A., & Miravitlles, M. (2013) · Journal of Infection · doi:10.1016/j.jinf.2013.08.010 · Cited by 85
The heterogeneity of systemic inflammation in bronchiectasis
Saleh, A., Chalmers, J. D., Soyza, A. D., Fardon, T. C., Koustas, S. O., Scott, J., Simpson, A. J., Brown, J., & Hurst, J. R. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.04.009 · Cited by 81
Primary Ciliary Dyskinesia
Lobo, J., Zariwala, M., & Noone, P. G. (2015) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0035-1546748 · Cited by 81
Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis
Wilson, R. C., Aksamit, T. R., Aliberti, S., Soyza, A. D., Elborn, J. S., Goeminne, P., Hill, A. T., Menéndez, R., & Polverino, E. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.06.007 · Cited by 81
Neutrophilic inflammation in bronchiectasis
Chalmers, J. D., Metersky, M. L., Aliberti, S., Morgan, L. C., Fucile, S., LAUTERIO, M., & McDonald, P. P. (2025) · European Respiratory Review · doi:10.1183/16000617.0179-2024 · Cited by 84
Lung function, symptoms and inflammation during exacerbations of non-cystic fibrosis bronchiectasis: a prospective observational cohort study
Brill, S., Patel, A. R. C., Singh, R., Mackay, A. J., Brown, J., & Hurst, J. R. (2015) · Respiratory Research · doi:10.1186/s12931-015-0167-9 · Cited by 77
Longitudinal Nasopharyngeal Carriage and Antibiotic Resistance of Respiratory Bacteria in Indigenous Australian and Alaska Native Children with Bronchiectasis
Hare, K. M., Singleton, R. J., Grimwood, K., Valery, P. C., Cheng, A. C., Morris, P. S., Leach, A. J., Smith‐Vaughan, H., Chatfield, M. D., Redding, G. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070478 · Cited by 73
Clinical care of children with primary ciliary dyskinesia
Lucas, J. S., Alanin, M. C., Collins, S. A., Harris, A. L., Johansen, H. K., Nielsen, K. G., Papon, J., Robinson, P. J., & Walker, W. T. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1360770 · Cited by 73
Long‐term macrolides for non‐cystic fibrosis bronchiectasis: A systematic review and meta‐analysis
Wu, Q., Shen, W., Cheng, H., & Zhou, X. (2014) · Respirology · doi:10.1111/resp.12233 · Cited by 72
Safety and efficacy of the human neutrophil elastase inhibitor BAY 85-8501 for the treatment of non-cystic fibrosis bronchiectasis: A randomized controlled trial
Watz, H., Nagelschmitz, J., Kirsten, A., Pedersen, F., van der Mey, D., Schwers, S., Bandel, T.-J., & Rabe, K. F. (2019) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2019.03.009 · Cited by 74
The impact of acute air pollution fluctuations on bronchiectasis pulmonary exacerbation: a case-crossover analysis
Goeminne, P., Cox, B., Finch, S., Loebinger, M. R., Bedi, P., Hill, A. T., Fardon, T. C., de Hoogh, K., Nawrot, T. S., & Chalmers, J. D. (2018) · European Respiratory Journal · doi:10.1183/13993003.02557-2017 · Cited by 70
Long-term macrolide maintenance therapy in non-CF bronchiectasis: Evidence and questions
HAWORTH, C. S., Bilton, D., & Elborn, J. S. (2014) · Respiratory Medicine · doi:10.1016/j.rmed.2014.09.005 · Cited by 70
Burden and trends of hospitalisations associated with pulmonary non-tuberculous mycobacterial infections in Germany, 2005–2011
Ringshausen, F. C., Apel, R.-M., Bange, F., Roux, A. D., Pletz, M. W., Rademacher, J., Suhling, H., Wagner, D., & Welte, T. (2013) · BMC Infectious Diseases · doi:10.1186/1471-2334-13-231 · Cited by 70
The Efficacy and Safety of Inhaled Antibiotics for the Treatment of Bronchiectasis in Adults
Cordeiro, R. J. P. D. M., Choi, H., HAWORTH, C. S., & Chalmers, J. D. (2024) · CHEST Journal · doi:10.1016/j.chest.2024.01.045 · Cited by 69
Bronchiectasis in severe asthma
Coman, I., Pola-Bibian, B., Barranco, P., Vilà-Nadal, G., Domínguez‐Ortega, J., Romero, D., Villasante, C., & Quirce, S. (2018) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2018.02.016 · Cited by 69
British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease
Smith, D., Rand, I. D., Addy, C., Collyns, T. A., Hart, S. P., Mitchelmore, P. J., Rahman, N. M., & Saggu, R. (2020) · Thorax · doi:10.1136/thoraxjnl-2019-213929 · Cited by 70
The Lung Immune Response to NontypeableHaemophilus influenzae(Lung Immunity to NTHi)
King, P. T., & Sharma, R. (2015) · Journal of Immunology Research · doi:10.1155/2015/706376 · Cited by 74

Authors: Wong, C., Jayaram, L., Karalus, N., Eaton, T., Tong, C., Hockey, H., Milne, D., Fergusson, W., Tuffery, C., Sexton, P., Storey, L., & Ashton, T.
Affiliations: Middlemore Hospital (NZ)
Monash Medical Centre (AU)
Waikato Hospital (NZ)
Auckland City Hospital (NZ)
University of Auckland (NZ)
Corresponding author: Wong, Conroy
ORCID: Wong, Conroy
Jayaram, Lata
Hockey, Hans
Milne, David
Sexton, Paul
Ashton, Toni
Venue: The Lancet
Publisher: Elsevier BV
Published: 2012-08
Volume: 380
Issue: 9842
Pages: 660-667
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(12)60953-2
OpenAlex: W2169216429
Cited by: 600
References: 38
Citations by year: 2026: 33 · 2025: 22 · 2024: 29 · 2023: 21 · 2022: 33 · 2021: 36 · 2020: 37 · 2019: 48 · 2018: 56 · 2017: 59 · 2016: 45 · 2015: 52 · 2014: 67 · 2013: 55 · 2012: 6
FWCI: 46.39
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
Keywords: azithromycin, non-cystic fibrosis bronchiectasis, pulmonary exacerbations, macrolide antibiotics, anti-inflammatory therapy, lung function, health-related quality of life, St George's Respiratory Questionnaire, FEV1, EMBRACE trial, antibiotic prophylaxis, immunomodulation, adverse events
MeSH terms: Adult, Aged, Anti-Bacterial Agents, Bronchiectasis, Cystic Fibrosis, Double-Blind Method, Drug Administration Schedule, Female, Forced Expiratory Volume, Humans, Male, Middle Aged, Quality of Life, Vital Capacity, Treatment Outcome, Azithromycin, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks